Metabolic complications during regional citrate anticoagulation in continuous venovenous hemodialysis: Single-center experience

被引:76
|
作者
Morgera, S
Scholle, C
Voss, G
Haase, M
Vargas-Hein, O
Krausch, D
Melzer, C
Rosseau, S
Zuckermann-Becker, H
Neumayer, HH
机构
[1] Humboldt Univ, Charite, Dept Nephrol, D-1086 Berlin, Germany
[2] Humboldt Univ, Charite, Dept Anesthesiol, D-1086 Berlin, Germany
[3] Humboldt Univ, Charite, Dept Cardiol, D-1086 Berlin, Germany
[4] Humboldt Univ, Charite, Dept Infect Dis, D-1086 Berlin, Germany
[5] Humboldt Univ, Charite, Dept Surg, D-1086 Berlin, Germany
来源
NEPHRON CLINICAL PRACTICE | 2004年 / 97卷 / 04期
关键词
citrate anticoagulation; continuous renal replacement therapy; metabolic complications;
D O I
10.1159/000079171
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Regional anticoagulation with trisodium citrate is an effective form of anticoagulation for continuous renal replacement therapy (CRRT) in patients at a high risk of bleeding. In a prospective, observational study we compared an established regional citrate anticoagulation protocol [Mehta R et al: Kidney Int 1990; 38: 976-981] versus a standard heparin anticoagulation protocol focusing on acid-base and electrolyte derangements as well as on cost effectiveness. Methods and Results: 209 patients were included in the study. In 37 patients, citrate was used as the sole anticoagulant, 87 patients received low-dose heparin plus citrate, and 85 patients received only heparin as anticoagulant. A customized dialysate solution was used for citrate-anticoagulated CRRT (no buffer, no calcium, reduced sodium concentration). Filter life was significantly higher during citrate anticoagulation compared to heparin anticoagulation (80.2 +/- 60 vs. 30.2 +/- 32 h; p < 0.001). No difference was found between citrate and citrate-heparin anticoagulation (p = 0.310). Metabolic alkalosis was observed in more than 50% of patients on citrate anticoagulation. Alkalosis developed within the first 72 h after initiating treatment and could be reversed in almost all cases by increasing the dialysate flow rate. Hypercalcemia was observed in 13 patients on citrate anticoagulation. Patients with impaired liver function were particularly at risk. Systemic hypocalcemia, hypernatremia, and anion gap acidosis were not observed. Citrate anticoagulation was well tolerated hemodynamically. A longer filter life during citrate anticoagulation translated into a significant cost reduction compared to standard heparin anticoagulation (p < 0.01). Conclusion: Regional anticoagulation with trisodium citrate in combination with a customized calcium-free dialysate is a safe and effective alternative to a heparin-based anticoagulation regimen. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:C131 / C136
页数:6
相关论文
共 50 条
  • [41] Iatrogenic hypercalcaemia inducing Takotsubo cardiomyopathy in regional citrate anticoagulation for continuous venovenous haemodialysis
    Fearnley, R. A.
    Gatward, J. J.
    Gattas, D. J.
    ANAESTHESIA AND INTENSIVE CARE, 2014, 42 (04) : 520 - 521
  • [42] Treatment of metabolic alkalosis during continuous renal replacement therapy with regional citrate anticoagulation
    Kindgen-Milles, D.
    Amman, J.
    Kleinekofort, W.
    Morgera, S.
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2008, 31 (04): : 363 - 366
  • [43] REGIONAL CITRATE ANTICOAGULATION FOR CONTINUOUS ARTERIOVENOUS HEMODIALYSIS IN CRITICALLY ILL PATIENTS
    MEHTA, RL
    MCDONALD, BR
    AGUILAR, MM
    WARD, DM
    KIDNEY INTERNATIONAL, 1990, 38 (05) : 976 - 981
  • [44] Continuous venovenous hemodiafiltration in the treatment of newborns with an inborn metabolic disease: a single center experience
    Akduman, Hasan
    Okulu, Emel
    Eminoglu, Fatma Tuba
    Kendirli, Tanil
    Tunc, Gaffari
    Azapagasi, Ebru
    Perk, Oktay
    Erdeve, Omer
    Atasay, Begum
    Arsan, Saadet
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2020, 50 (01) : 12 - 17
  • [45] PROPHYLACTIC ANTICOAGULATION IN CHILDREN UNDERGOING HEMODIALYSIS: A 10-YEAR SINGLE-CENTER EXPERIENCE
    Ortega, Federico Moral
    Ghattas, Yasmine
    Katsoufis, Chryso
    Seeherunvong, Wacharee
    Chandar, Jayanthi
    Abitbol, Carolyn
    DeFreitas, Marissa
    Corrales-Medina, Fernando
    PEDIATRIC BLOOD & CANCER, 2023, 70 : S172 - S173
  • [46] Regional Citrate Anticoagulation in Predilution Continuous Venovenous Hemofiltration Using Prismocitrate 10/2 Solution
    Shum, Hoi-Ping
    Chan, King-Chung
    Yan, Wing-Wa
    THERAPEUTIC APHERESIS AND DIALYSIS, 2012, 16 (01) : 81 - 86
  • [47] A Retrospective Review of the Use of Regional Citrate Anticoagulation in Continuous Venovenous Hemofiltration for Critically Ill Patients
    Leung, Anne Kit-Hung
    Shum, Hoi-Ping
    Chan, King-Chung
    Chan, Stanley Choi-Hung
    Lai, Kang Yiu
    Yan, Wing-Wa
    CRITICAL CARE RESEARCH AND PRACTICE, 2013, 2013
  • [48] Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding
    Palsson, R
    Niles, JL
    KIDNEY INTERNATIONAL, 1999, 55 (05) : 1991 - 1997
  • [49] A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration
    Fealy, N.
    Baldwin, I.
    Johnstone, M.
    Egi, M.
    Bellomo, R.
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2007, 30 (04): : 301 - 307
  • [50] Continuous Venovenous Hemofiltration in Children Less Than or Equal to 10 kg: A Single-Center Experience
    Kaempfen, Siree
    Dutta-Kukreja, Pompa
    Mok, Quen
    PEDIATRIC CRITICAL CARE MEDICINE, 2017, 18 (02) : E70 - E76